Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Status
- RECRUITING
- Phase
- PHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
- Status
- SUSPENDED
- Phase
- PHASE2
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
Two Schemes Response in Multiple Myeloma
- Status
- RECRUITING
- Phase
- N/A
An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
- Status
- RECRUITING
- Phase
- NA
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Status
- RECRUITING
- Phase
- NA
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Status
- RECRUITING
- Phase
- PHASE2
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Status
- RECRUITING
- Phase
- PHASE3
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Status
- RECRUITING
- Phase
- PHASE2
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
- Status
- RECRUITING
- Phase
- PHASE2